Incretin mimetic drugs (GLP-1 agonists and GIP agonists) are already approved by the USFDA for reducing IR in T2DM and are now under trials to observe their efficacy in MASLD. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.